Bristol Myers Squibb announced that the FDA has accepted its supplemental Biologics License Application for Opdivo®, in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma, based on results from the CheckMate -649 trial.
[Bristol Myers Squibb]
0